论文部分内容阅读
目的观察依那西普治疗类风湿性关节炎(RA)的疗效及安全性。方法76例RA患者随机分为两组,对照组36例给予甲氨蝶呤和硫酸羟氯喹,治疗组40例应用依那西普,两组疗程均为3个月。结果治疗组总有效率显著高于对照组(P<0.05),在关节疼痛数、关节压痛积分、关节肿胀积分、晨僵时间及20m步行时间等方面均与用药前有显著差异(P<0.05或P<0.01),治疗组不良反应发生率显著低于对照组(P<0.05)。结论依那西普治疗RA疗效优于传统的甲氨蝶呤和羟氯喹,且不良反应少而轻微,安全性好。
Objective To observe the efficacy and safety of etanercept in the treatment of rheumatoid arthritis (RA). Methods A total of 76 patients with RA were randomly divided into two groups. The control group received methotrexate and hydroxychloroquine, while the control group received 40 mg of etanercept. The course of treatment was 3 months in both groups. Results The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05), and there was significant difference in the joint pain count, joint tenderness score, joint swelling score, morning stiffness time and walking time of 20m before treatment Or P <0.01). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion Etanercept is superior to traditional methotrexate and hydroxychloroquine in the treatment of RA with few and minor side effects and good safety.